GO
Loading...

Actavis Inc

More

  • Nov 17- Allergan Inc agreed to be bought by Actavis Plc for $66 billion, putting an end to a hostile bid by activist investor William Ackman and Valeant Pharmaceuticals International Inc.. The offer values Allergan at $219 per share and is $6 billion more than the price Valeant had last offered to pay. Allergan shares rose 6.6 percent to $211, earning Ackman a...

  • Nov 17- Valeant Pharmaceuticals International Inc Chief Executive Michael Pearson said on Monday that the company can't justify matching Actavis Plc's $219 per share bid for Allergan Inc..

  • Allergan agrees to Actavis deal for $66 billion Monday, 17 Nov 2014 | 9:20 AM ET

    Nov 17- Allergan Inc agreed to be bought by Actavis Plc for $66 billion, more than $12 billion above the current value of a hostile bid by activist investor William Ackman and Valeant Pharmaceuticals International Inc. The offer values Allergan at $219 per share, compared with its Friday close of $198.65. Valeant's latest cash-and-stock offer is currently...

  • *Baker Hughes rallies on Halliburton deal; crude futures fall. *DreamWorks shares slide as Hasbro talks stall. Merger and acquisition news partly offset the declines as Halliburton said it would buy Baker Hughes and Allergan is close to a buyout by Actavis.

  • US STOCKS-Futures slip as Japan dips into recession Monday, 17 Nov 2014 | 7:42 AM ET

    *Merger and acquisition news partly offset the declines as Halliburton said it would buy Baker Hughes and Allergan is close to a buyout deal by Actavis. *Baker Hughes rose 16.4 percent on news Halliburton would acquire it in a cash and stock transaction of about $34.6 billion. *Allergan added 4.5 percent as the Actavis buyout values the company as high as $65.5...

  • Nov 16- Allergan Inc is close to a buyout deal worth up to $65.5 billion by Actavis Plc, one that could end months of pursuit by Canada's Valeant Pharmaceuticals and William Ackman's hedge fund, Pershing Square Capital Management, according to a person familiar with the matter. Actavis may pay Allergan between $215 and $220 per share, with the final price likely...

  • BUSINESS-NEWS-SCHEDULE AT 2200 GMT / 5 PM ET Sunday, 16 Nov 2014 | 4:46 PM ET

    WASHINGTON- President Barack Obama defends the transparency of his signature healthcare law after a White House adviser on the reform said the law passed, in part, because of the "stupidity" of American voters. ALLERGAN, ACTAVIS NEAR DEAL, ANNOUNCEMENT AS EARLY AS MONDAY. NEW YORK- Allergan nears a deal to merge with Actavis Plc, with an announcement coming as soon as...

  • Nov 16- Allergan Inc is near a deal to merge with Actavis Plc, with an agreement to be announced as soon as Monday, according to a person familiar with the matter. Actavis is likely to pay Allergan between $210 and $220 per share, according to the source. Actavis and Allergan declined to comment.

  • Actavis would likely pay Allergan between $210 and $220 per share, according to the source.

  • NEW YORK, Nov 16- Allergan Inc is near making a friendly deal with Actavis Plc, the Wall Street Journal reported on Sunday, citing people familiar with the matter.

  • LONDON, Nov 14- Pfizer appears unlikely to make a fresh bid for AstraZeneca in 12 days time, when an enforced cooling-off period ends, and the U.S. drugmaker is now weighing other less risky targets. People with direct knowledge of the situation said Pfizer has been reviewing different takeover scenarios with a U.S. investment bank ahead of Nov. 26, when it is allowed...

  • Nov 12- Merger talks between Allergan Inc and white knight Actavis Plc are focused on narrowing a gap of about $3 billion between what has been offered and what is wanted, Bloomberg reported on Wednesday. Actavis is willing to pay around $200 per share, or $60 billion, while Allergan wants more than $210 per share, Bloomberg said. The amended laws now include a...

  • Nov 12- Actavis Plc is in talks to buy Allergan Inc for at least $60 billion in a deal that could culminate this month, Bloomberg reported, citing sources familiar with the matter. The two companies are trying to narrow a gap of about $3 billion between what Actavis wants to pay and what Allergan is asking for, Bloomberg reported. Allergan, which is trying to fend off a...

  • BOSTON, Nov 7- Valeant Pharmaceuticals International Inc can pay "substantially" more for Allergan Inc and should get a fair shot at buying it, William Ackman, the Botox maker's biggest shareholder, said on Friday. Ackman wrote to Allergan's board the day after the company said it was discussing a merger with another company, widely reported to be Actavis, to fend...

  • BOSTON, Nov 7- Valeant Pharmaceuticals International Inc can pay "substantially" more for Allergan Inc and should get a fair shot at buying it, William Ackman, the Botox maker's biggest shareholder, said on Friday. Ackman said this in a letter to Allergan's board the day after the company said it was discussing a merger with another company, widely reported to be...

  • The two companies were close to inking a deal, but Botox maker Allergan balked after its due diligence raised questions over inventory levels, the people said, requesting anonymity because the negotiations were confidential. Earlier on Thursday, Allergan said it was in discussions with another party that a source familiar with the situation identified as...

  • Nov 5- The top executive of Actavis Inc, which sources say is pursuing a "white knight" acquisition of Allergan Inc, made a case Wednesday for doing a deal, saying the drug company could continue to grow earnings and manage its debt load. "If there was an opportunity, I think we've demonstrated as a team that if it was the right strategic opportunity with strong...

  • Nov 3- Botox maker Allergan Inc, which is fending off an acquisition by Valeant Pharmaceuticals Inc, said on Monday that it had been approached by another party regarding a potential transaction. Valeant and Pershing Square Capital Management, which owns nearly a 10 percent stake in Allergan, made an offer now worth $55 billion for Allergan at the end of April.

  • Nov 3- Allergan Inc, which is fending off an acquisition by Valeant Pharmaceuticals Inc, said on Monday that it had been approached by another party regarding a potential transaction. Valeant and Pershing Square Capital Management made an offer, now worth $55 billion, for Allergan at the end of April. Pershing Square owns nearly a 10 percent stake in Allergan.

  • Oct 20- Generic drugmaker Actavis Plc and France's Sanofi SA are among the suitors for privately held Omega Pharma NV, Bloomberg reported, citing people familiar with the matter. Other bidders for the Belgian consumer healthcare company include Perrigo Co and private German drugmaker Boehringer Ingelheim GmBH, the sources told Bloomberg.